Pravastatin
Brand name: Pravachol (pravastatin sodium)
Quick Facts
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Primary prevention — reduction of MI, revascularization, and CV mortality | Adults with elevated LDL-C without clinically evident CHD | Adjunct to diet | FDA Approved |
| Secondary prevention — reduction of coronary death, MI, revascularization, stroke or TIA, and slowing progression of coronary atherosclerosis | Adults with clinically evident CHD | Adjunct to diet | FDA Approved |
| Primary hyperlipidemia | Adults | Adjunct to diet | FDA Approved |
| Heterozygous familial hypercholesterolemia (HeFH) | Pediatric patients ≥8 years (note: pravastatin uniquely approved from age 8, vs age 10 for most statins) | Adjunct to diet | FDA Approved |
| Hypertriglyceridemia (Fredrickson type IV) | Adults | Adjunct to diet | FDA Approved |
| Primary dysbetalipoproteinemia (Fredrickson type III) | Adults | Adjunct to diet | FDA Approved |
Pravastatin is one of the most extensively studied statins, with cardiovascular outcome data spanning more than 47,600 patient-years across the WOSCOPS, CARE, LIPID, PROSPER, and ALLHAT-LLT trials. The Pravastatin Pooling Project (WOSCOPS + CARE + LIPID, >112,000 patient-years) established class-leading long-term safety. The 2018 AHA/ACC Cholesterol Guideline classifies pravastatin 40–80 mg as moderate intensity (LDL-C reduction ~30–37%) and pravastatin 10–20 mg as low intensity (<30%); no pravastatin dose meets the high-intensity threshold (≥50% LDL-C reduction). Despite this lower potency, pravastatin remains a useful agent because of its hydrophilic profile, lack of CYP3A4-driven interactions, and exceptional long-term tolerability — especially in transplant recipients, HIV patients on protease inhibitors, frail elderly patients, and those with recurrent statin-associated muscle symptoms on lipophilic statins.
Statin selection in solid organ transplant recipients on cyclosporine — although the dose is capped at 20 mg, pravastatin and fluvastatin are the preferred statins in transplant patients due to minimal accumulation; supported by Olbricht 1997 transplant pharmacokinetic data. Evidence: moderate quality.
Lipid management in HIV patients on antiretroviral therapy — pravastatin and pitavastatin are preferred in HIV patients on ritonavir- or cobicistat-boosted regimens (most other statins are either contraindicated or carry meaningful interaction risk). Evidence: moderate quality (clinical guidelines).
Stroke prevention in elderly patients — extrapolation from PROSPER (n=5,804, 70–82 years) showing reduction in coronary events and modest stroke benefit. Evidence: moderate quality.
Pediatric HeFH from age 8 — pravastatin is FDA-approved from age 8, earlier than most other statins. Evidence: high quality (pivotal trial).
Dosing
Pravastatin is taken orally once daily, at any time of day, with or without food — a notable convenience advantage over short-half-life statins like simvastatin and lovastatin that require evening administration. Reassess LDL-C as early as 4 weeks after initiation or dose change. Maximum recommended dosage is 80 mg/day; if the patient is not at LDL-C goal on 80 mg, switch to a higher-intensity statin (atorvastatin 40–80 or rosuvastatin 20–40) rather than further escalation. Note that pravastatin 10–20 mg is classified as low intensity by the 2018 AHA/ACC guideline; only 40–80 mg meets moderate intensity.
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| ASCVD primary prevention — adults with elevated LDL-C and high CV risk | 40 mg | 40–80 mg | 80 mg/day | 40 mg dose used in WOSCOPS (~31% reduction in coronary events over 4.9 yr) Per AHA/ACC 2018: 40–80 mg = moderate intensity |
| ASCVD secondary prevention — established CHD, post-MI, post-stroke, or PAD | 40 mg | 40–80 mg | 80 mg/day | 40 mg dose used in CARE and LIPID; if LDL-C goal not met on 80 mg, switch to high-intensity statin Pravastatin generally not first-line for high-risk secondary prevention; consider it primarily when high-intensity statins are not tolerated |
| Primary hyperlipidemia — adults | 40 mg | 40 mg | 80 mg/day | Per VOYAGER/pivotal data: ~28% LDL-C reduction at 40 mg, ~37% at 80 mg |
| Heterozygous familial hypercholesterolemia (HeFH) — pediatric 8–13 years | 20 mg | 20 mg | 20 mg/day | Doses >20 mg not studied in this age group Pivotal pediatric study (n=214, ages 8–18) supports use; safety similar to placebo |
| Heterozygous familial hypercholesterolemia (HeFH) — pediatric 14–18 years | 40 mg | 40 mg | 40 mg/day | Doses >40 mg not studied in this age group; counsel adolescent females on contraception |
| Hypertriglyceridemia / primary dysbetalipoproteinemia | 40 mg | 40–80 mg | 80 mg/day | Modest TG reduction (~10–20%); consider fenofibrate or icosapent ethyl if TG remain elevated Gemfibrozil should be avoided per current PI |
Population-Specific Adjustments
| Population | Starting / Recommended Dose | Maximum Dose | Notes |
|---|---|---|---|
| Severe renal impairment | 10 mg once daily (use generic; Pravachol 10 mg no longer marketed) | 40 mg/day | Mild–moderate renal impairment requires no dose adjustment Severe CKD = 69% higher AUC of inactive metabolite |
| Concomitant cyclosporine | 10 mg once daily (use generic 10 mg) | 20 mg/day | Cyclosporine raises pravastatin AUC by ~282%; pravastatin is nonetheless a preferred statin in transplant recipients due to its safety profile |
| Concomitant clarithromycin or erythromycin | Standard initiation | 40 mg/day | Clarithromycin raises pravastatin AUC by ~110%. Azithromycin has minimal effect and is the preferred macrolide alternative |
| SLCO1B1 *5 carriers (poor or decreased OATP1B1 function) | Standard initiation; cautious titration | Consider keeping at ≤40 mg/day | Per CPIC 2022 guidance: increased exposure may translate to higher SAMS risk if dose >40 mg/day. If higher potency needed, consider alternative statin or combination therapy |
| Concomitant darunavir/ritonavir | Cautious initiation | Use lowest effective dose; monitor for muscle symptoms | Darunavir/ritonavir raises pravastatin AUC by ~81%. Pravastatin remains a preferred statin in HIV patients (most other statins are worse choices) |
| Concomitant boceprevir (HCV protease inhibitor) | Cautious initiation | Use lowest effective dose; monitor | Boceprevir raises pravastatin AUC by ~63% |
| Mild-moderate hepatic impairment | Cautious initiation | No specific maximum stated; large interindividual variability | AUC varied 18-fold in cirrhotic patients vs 5-fold in healthy controls. Acute liver failure or decompensated cirrhosis is a contraindication |
| Elderly (≥65 years) | Standard initiation; consider 20–40 mg start | Standard maxima | AUC ~25–50% higher in elderly subjects but no accumulation; PROSPER demonstrated CV benefit in patients aged 70–82 |
Pravastatin is the only major statin that is both hydrophilic and not a clinically significant CYP3A4 substrate. The hydrophilic profile reduces extrahepatic tissue penetration (less brain and muscle exposure), and the bypass of CYP3A4 metabolism eliminates the largest source of statin drug-drug interactions. These properties make pravastatin a genuinely useful tool when other statins are problematic — for example in transplant recipients on cyclosporine, HIV patients on ritonavir-boosted antiretrovirals, patients on chronic azole antifungal therapy, and patients with recurrent muscle symptoms on lipophilic statins. The trade-off is lower potency: no pravastatin dose reaches high-intensity LDL-C reduction (≥50%).
The current Pravachol PI states pravastatin can be taken at any time of day. Older labelling and pharmacokinetic studies have shown that bedtime dosing decreases systemic bioavailability by ~60% but is associated with a marginally greater (not statistically significant) lipid-lowering effect, suggesting greater hepatic extraction. Practically, if a patient prefers evening dosing for habit reasons it is acceptable, but morning dosing is no longer discouraged.
Pharmacology
Mechanism of Action
Pravastatin is a reversible, competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. Unlike simvastatin and lovastatin, pravastatin is administered as the active β-hydroxyacid form — no hepatic activation step is required. Reduced intracellular cholesterol upregulates LDL receptors on hepatocyte surfaces, accelerating clearance of LDL particles from circulation. Net effects are dose-dependent reductions in LDL-C (~22% at 10 mg, ~28% at 40 mg, and ~37% at 80 mg), apolipoprotein B, non-HDL-C, and total cholesterol, with smaller reductions in triglycerides (~10–20%) and modest increases in HDL-C (~5–10%). Pravastatin is a substrate of the OATP1B1 hepatic uptake transporter, which mediates its concentration in the liver and accounts for its clinically relevant interactions with cyclosporine, gemfibrozil, and certain antiretrovirals.
Pravastatin’s hydrophilicity (partition coefficient 0.59 at pH 7.0) limits passive diffusion into peripheral tissues, including skeletal muscle and the central nervous system, which contributes to its low rates of myopathy and absence of significant cognitive complaints. Crucially, pravastatin is not metabolized by CYP3A4 to a clinically significant extent: its major biotransformation pathways are isomerization to 6-epi pravastatin and the 3α-hydroxyisomer (SQ 31,906) and enzymatic ring hydroxylation to SQ 31,945. This metabolic profile spares pravastatin from the dense network of CYP3A4-mediated interactions that complicate simvastatin, atorvastatin, and lovastatin therapy.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Tmax 1–1.5 h; absolute bioavailability ~17%; oral absorption ~34%; food reduces AUC ~31% and Cmax ~49% but lipid-lowering efficacy is similar with or without food | No food restrictions; can be taken any time of day |
| Distribution | Plasma protein binding ~50% (lowest among statins); hydrophilic — limited penetration into peripheral tissues including muscle and brain | Less extrahepatic exposure than lipophilic statins; contributes to favorable myopathy profile |
| Metabolism | Isomerization to 6-epi pravastatin and 3α-hydroxyisomer (SQ 31,906; 1/10 to 1/40 the activity of parent); enzymatic ring hydroxylation to SQ 31,945 (inactive); hepatic extraction ratio 0.66; not a clinically significant CYP3A4 substrate | Cleanest interaction profile of any statin — grapefruit juice, azole antifungals (other than fluconazole at high doses), and CYP3A4 inhibitor calcium channel blockers do not require dose adjustment |
| Elimination | ~20% urinary excretion, ~70% fecal excretion; t½ ~1.8 h (parent), ~77 h (total radioactivity); 47% renal vs 53% non-renal clearance after IV administration | Severe renal impairment requires dose reduction; mild–moderate renal impairment does not |
Side Effects
Pravastatin has one of the most extensively studied long-term safety profiles of any statin. The Pravastatin Pooling Project combined data from WOSCOPS, CARE, and LIPID — accumulating >112,000 person-years of randomized, placebo-controlled exposure to pravastatin 40 mg daily — and showed no excess of non-cardiovascular serious adverse events, no excess cancers, equivalent rates of liver function abnormalities (1.4% vs 1.4% placebo), and no cases of severe myopathy. Frequencies below are drawn from the FDA Pravachol PI Tables 1 and 2.
| Adverse Effect | Pravastatin 40 mg (N=10,764) | Placebo (N=10,719) |
|---|---|---|
| Musculoskeletal pain | 24.9% | 24.4% |
| Upper respiratory tract infection | 21.2% | 20.2% |
| Musculoskeletal traumatism | 10.2% | 9.6% |
| Chest pain | 10.0% | 9.8% |
Note: rates in long-term trials reflect background population incidence over 4–5 years of follow-up rather than drug attribution. Differences vs placebo are small (≤1 percentage point) for all very common reactions.
| Adverse Effect | Incidence (Short-Term Trials) | Clinical Note |
|---|---|---|
| Nausea / vomiting | 7.4% (vs placebo 7.1%) | Mild and usually transient; may improve if taken with food |
| Diarrhea | 6.7% (vs placebo 5.6%) | Usually mild; rule out alternative causes if persistent |
| Headache | 6.3% (vs placebo 4.6%) | Generally mild; usually resolves within weeks |
| Upper respiratory infection | 5.9% (vs placebo 5.8%) | Background rate; not drug-attributable |
| Rash | 4.5% (vs placebo 1.4%) | Most cases mild; discontinue if severe or systemic features develop |
| Asymptomatic CK elevation | 4.1% (vs placebo 3.6%) | Most attributable to non-cardiac CK fraction; not by itself an indication to stop |
| Asymptomatic ALT elevation | 2.9% (vs placebo 1.2%) | Persistent elevation >3× ULN occurs in ~1% of pravastatin AND placebo patients per long-term trials; rarely clinically significant |
| Cough | 2.5% (vs placebo 1.7%) | Usually mild and transient |
| Myalgia | 2.3% (vs placebo 1.2%) | Real-world rates are higher; pravastatin has the lowest myopathy rate among major statins |
| Influenza | 2.0% (vs placebo 0.7%) | Background rate |
| γ-GT elevation | 2.0% (vs placebo 1.2%) | Asymptomatic; not by itself an indication to discontinue |
| New-onset diabetes (statin class effect) | ~1–2% excess risk | HbA1c and fasting glucose may rise modestly; CV benefit substantially outweighs glycemic risk |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Myopathy (CK >10× ULN with symptoms) | <0.1% in clinical trials | First few months | Discontinue; rechallenge with lower dose or alternate statin only after resolution |
| Rhabdomyolysis | Very rare (no cases in WOSCOPS+CARE+LIPID pooled, >112,000 patient-years) | Weeks–months | Stop drug immediately; check CK and renal function; aggressive hydration; avoid all statins until resolved |
| Immune-mediated necrotizing myopathy (IMNM) | Very rare (~2 per million person-years across statin class) | Months–years; persists or worsens after stopping | Permanent discontinuation; check anti-HMGCR antibody; refer to neurology / rheumatology for immunosuppressive therapy |
| Fatal and non-fatal hepatic failure | Rare (post-marketing) | Weeks–months | Discontinue if jaundice or hyperbilirubinemia; evaluate for other causes |
| Hypersensitivity (anaphylaxis, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS) | Rare (post-marketing) | Days–weeks | Permanent discontinuation; avoid all statins after anaphylaxis or severe cutaneous reaction |
| Cognitive impairment (memory loss, confusion — usually reversible) | Rare (post-marketing, statin class label) | Days to years; resolution typically within weeks of stopping | Trial of discontinuation if temporally related; not a contraindication to future statin therapy |
| Interstitial lung disease, peripheral neuropathy, thrombocytopenia, pancreatitis (statin class) | Very rare (post-marketing) | Months–years | Discontinue if temporally related and other causes excluded |
| Lupus-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, hemolytic anemia (statin class, post-marketing) | Very rare | Months–years | Discontinue and refer to rheumatology for evaluation |
| Reason for Discontinuation | Context | Comment |
|---|---|---|
| Mild non-specific gastrointestinal complaints | Most common reason in long-term trials | Often settles with continued therapy or food administration |
| Hepatic transaminase elevation | ~1% develop persistent ALT/AST >3× ULN (similar to placebo in long-term trials) | Many cases resolve with continued therapy or after brief interruption |
| Nausea | Top short-term-trial reason | Usually mild; may improve with food |
| Myalgia / muscle symptoms | Lowest rate among major statins | Often manageable; pravastatin is a common rescue option for patients intolerant to lipophilic statins |
| Hypersensitivity | Permanent discontinuation indicated | Switch class if needed |
Pediatric data (24-month controlled trial in 214 HeFH patients ages 8–18.5; 53% female): adverse-reaction profile generally similar to placebo with influenza and headache the most common reactions in both groups. No detectable effect on growth or sexual maturation; doses >40 mg/day not studied in this population.
Pravastatin’s hydrophilicity, low protein binding (~50%), and minimal CYP3A4 metabolism translate into one of the lowest myopathy risk profiles among statins. In the Pravastatin Pooling Project (WOSCOPS + CARE + LIPID, >112,000 patient-years), no cases of severe myopathy were reported, and only 3 pravastatin and 7 placebo patients had medication withdrawn for CK elevation. This makes pravastatin an evidence-based first choice when re-trialing statin therapy in a patient with documented intolerance to lipophilic statins (simvastatin, atorvastatin, lovastatin). Consider every-other-day dosing as a further dose-reduction strategy in highly intolerant patients.
Drug Interactions
Pravastatin has the cleanest drug-interaction profile of any major statin. Because it is not metabolized by CYP3A4 to a clinically significant extent, the long list of interactions that complicates simvastatin and atorvastatin therapy (azole antifungals, macrolide antibiotics, calcium channel blockers, grapefruit juice, cobicistat-containing antiretrovirals) does not apply to pravastatin in the same way. The clinically relevant interactions are mediated by the OATP1B1 hepatic uptake transporter (cyclosporine, gemfibrozil, certain antiretrovirals), additive muscle toxicity (fibrates, niacin, colchicine), or absorption interference (bile acid sequestrants, antacids).
Monitoring
-
Lipid Panel
Baseline; reassess as early as 4 weeks; then 4–12 weeks after dose change; then annually
Routine Confirm percent LDL-C reduction (~28% expected at 40 mg, ~37% at 80 mg). If >50% reduction is needed (high-intensity goal), switch to atorvastatin 40–80 mg or rosuvastatin 20–40 mg rather than escalate pravastatin. Adherence is a more common reason for inadequate response than non-response. -
ALT / AST
Baseline; thereafter only if symptoms
Trigger-based Routine periodic LFTs are no longer recommended. Repeat if patient develops jaundice, fatigue, abdominal pain, dark urine, or unexplained nausea. Discontinue if ALT/AST >3× ULN with symptoms or hyperbilirubinemia. Pravastatin is contraindicated in acute liver failure or decompensated cirrhosis. -
Creatine Kinase (CK)
Baseline only in high-risk patients; otherwise only if symptoms
Trigger-based High-risk = age ≥65, hypothyroidism, renal impairment, prior statin myopathy, concomitant cyclosporine, or concomitant clarithromycin. Check if patient develops myalgia, weakness, or dark urine. Stop if CK >10× ULN with symptoms. -
Medication Reconciliation
Every visit and at every new prescription
Routine Check for new OATP1B1 inhibitors (cyclosporine, gemfibrozil, clarithromycin, ritonavir-boosted antiretrovirals, boceprevir) and additive myotoxic agents (fibrates, niacin, colchicine). Pravastatin’s interaction profile is much cleaner than other statins, but the OATP1B1-mediated interactions still matter. -
HbA1c / Fasting Glucose
Baseline; periodically if at risk for diabetes
Routine Modest excess incidence of new-onset diabetes (mostly in patients with prediabetes). CV benefit greatly outweighs glycemic risk; do not stop the statin if A1c rises into diabetic range. -
Renal Function
Baseline; per overall comorbidity profile
Routine Estimate CrCl/eGFR before initiation and recheck if clinical change. Severe renal impairment requires starting at 10 mg with maximum 40 mg/day. -
TSH
If unexplained myalgia or rising CK
Trigger-based Unrecognized hypothyroidism is a major contributor to apparent statin intolerance and CK rise; treat the thyroid before declaring statin intolerance. -
INR (if on warfarin)
Stable INR before pravastatin initiation; closer monitoring on dose change
Trigger-based Pravastatin causes a small but real INR prolongation. Effect is meaningfully smaller than with rosuvastatin or fluvastatin. -
Adherence Check
Every clinical visit
Routine Approximately half of patients discontinue statins within 1 year of initiation. Open, non-judgemental questioning (“How often do you forget?”) yields more accurate information than yes/no adherence questions. -
Pregnancy Status
In females of reproductive potential, periodically
Trigger-based FDA removed the pregnancy contraindication from the Pravachol PI in May 2022 (following the July 2021 class-wide statement). Statins are generally discontinued during planned or confirmed pregnancy unless benefits clearly outweigh risk. Effective contraception is recommended during therapy.
Contraindications & Cautions
Absolute Contraindications (per current FDA Pravachol PI, May 2022)
- Acute liver failure or decompensated cirrhosis.
- Hypersensitivity to pravastatin or any excipient in the formulation (anaphylaxis, angioedema, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported).
Note on label history: Pregnancy and lactation contraindications were removed from the Pravachol label in the May 2022 revision, reflecting the FDA July 2021 class-wide drug safety communication. Older Pravachol labels and some generic labels may still list these as contraindications, but the most current authoritative US PI does not.
Relative Contraindications (Specialist Input Recommended)
- Pregnancy — although the FDA removed the contraindication in 2021–2022, statins are still typically discontinued during planned or confirmed pregnancy. Continued use is reasonable only in established ASCVD or HoFH where lipid-lowering benefit clearly outweighs theoretical fetal risk; document the explicit risk-benefit discussion.
- Lactation — pravastatin is present in human milk; breastfeeding is not recommended during therapy. If therapy is required postpartum, use formula or switch to a different agent if appropriate.
- Severe renal impairment — start at 10 mg/day; maximum 40 mg/day with close monitoring for myopathy.
- History of statin-induced rhabdomyolysis or immune-mediated necrotizing myopathy — IMNM is a permanent contraindication to all statins; uncomplicated SAMS may permit cautious rechallenge with pravastatin specifically (it is the most common rescue option for patients intolerant to lipophilic statins).
- Concomitant gemfibrozil — current PI states pravastatin is “not recommended” with gemfibrozil due to additive myotoxicity. Use fenofibrate as an alternative.
Use with Caution
- Age ≥65 years — frailty, polypharmacy, and lower muscle mass raise myopathy risk; consider starting at 20–40 mg. PROSPER demonstrated CV benefit at 40 mg in patients aged 70–82.
- Hypothyroidism — treat first; untreated hypothyroidism amplifies myopathy risk and may itself elevate CK.
- Concomitant cyclosporine, clarithromycin, erythromycin, or HIV/HCV protease inhibitors — observe specific dose caps (cyclosporine 20 mg max; clarithromycin/erythromycin 40 mg max). These interactions are clinically meaningful but pravastatin remains a preferred statin in transplant and HIV patients given the alternatives.
- Concomitant fibrates (especially fenofibrate), niacin (≥1 g/day), or colchicine — additive myotoxicity; counsel on muscle symptoms.
- Diabetes risk factors (prediabetes, metabolic syndrome) — small excess diabetes incidence; CV benefit nonetheless outweighs risk.
- Major surgery, sepsis, severe trauma, or other acute serious medical conditions — temporarily withhold pravastatin in any patient at high risk of rhabdomyolysis.
- Pediatric patients <8 years — efficacy and safety not established below age 8.
- SLCO1B1 *5 carriers (poor or decreased OATP1B1 function) — consider keeping pravastatin at ≤40 mg/day per CPIC 2022 guidance. If higher potency is needed, consider an alternative statin or combination therapy.
- Substantial chronic alcohol use or prior liver disease — increased risk of hepatic injury.
All HMG-CoA reductase inhibitors carry a class-wide warning regarding myopathy and rhabdomyolysis. Pravastatin has the lowest myopathy risk among statins (clinical-trial myopathy rate <0.1% with no severe cases reported in the WOSCOPS+CARE+LIPID pooled analysis), but the warning still applies. Risk factors include age ≥65 years, uncontrolled hypothyroidism, renal impairment, female sex, low body weight, and concomitant interacting drugs (especially cyclosporine, gemfibrozil, clarithromycin, ritonavir).
Counsel every patient to promptly report unexplained muscle pain, tenderness, weakness, or dark urine. Discontinue immediately if rhabdomyolysis is suspected or if CK rises >10× ULN with symptoms. Temporarily withhold pravastatin in any patient with an acute serious condition predisposing to rhabdomyolysis (sepsis, hypotension, dehydration, major surgery, severe metabolic or electrolyte disorder, uncontrolled seizures).
The FDA requested removal of the contraindication against statin use in pregnancy from the labelling of all statins. The Pravachol label was updated accordingly in May 2022. The change does not endorse routine use; it allows individualized risk-benefit decisions, particularly for women with HoFH, established ASCVD, or very high CV risk.
Most patients should still discontinue pravastatin on confirmation of pregnancy. Lactation remains a reason to defer therapy because of measurable infant exposure (pravastatin is present in human milk); patients who require ongoing statin therapy postpartum should not breastfeed.
Rare reports of IMNM, an autoimmune myopathy, have been associated with statin use, including pravastatin, with reports of recurrence when the same or a different statin was administered. IMNM is characterized by proximal muscle weakness and elevated CK that persist despite statin discontinuation, positive anti-HMG-CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive therapy.
Discontinue pravastatin if IMNM is suspected, refer to neurology or rheumatology for confirmatory testing, and avoid all statins in confirmed cases.
Patient Counselling
Purpose of Therapy
Pravastatin lowers LDL (“bad”) cholesterol by reducing the liver’s production of cholesterol. Lower LDL means less plaque buildup inside arteries, which reduces the chance of heart attacks, strokes, and the need for procedures such as stents or bypass surgery. The benefit accumulates over years — most patients are taking it for prevention rather than for symptom relief, so they may not “feel” anything different. Lifestyle measures (diet, exercise, weight control, smoking cessation) act on the same arteries and add to the benefit.
How to Take
Take one tablet once a day. Pravastatin can be taken at any time of day, with or without food — it does not need to be taken in the evening like some other statins. Pick a time that fits your daily routine and stick with it. If a dose is missed, take it as soon as remembered the same day; if it is almost time for the next dose, skip the missed one and continue normally. Do not double up. Unlike some other statins, grapefruit juice does not meaningfully interact with pravastatin, so dietary restrictions are not required. Do not stop the medicine without speaking to the prescriber, even if cholesterol numbers look good — stopping is when the protection fades.
Sources
- PRAVACHOL (pravastatin sodium) US Prescribing Information. Bristol-Myers Squibb; revised May 2022. Accessed via FDA Drugs@FDA. accessdata.fda.gov/drugsatfda_docs/label/2022/019898s070lbl.pdf Authoritative source for FDA-approved indications, dosing, contraindications, drug interactions (Tables 3 & 5), and adverse-reaction frequencies (Tables 1 & 2) cited in this monograph. Notable May 2022 update: removal of pregnancy and lactation contraindications.
- FDA Drug Safety Communication: FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy. July 20, 2021. fda.gov The 2021 labeling change removing the pregnancy contraindication for the entire statin class; reflected in the May 2022 Pravachol revision.
- Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (West of Scotland Coronary Prevention Study, WOSCOPS). N Engl J Med. 1995;333(20):1301-1307. doi:10.1056/NEJM199511163332001 Landmark primary prevention trial; 6,595 men with LDL-C 156–254 mg/dL randomized to pravastatin 40 mg or placebo for ~4.9 years; ~31% reduction in coronary events.
- Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE). N Engl J Med. 1996;335(14):1001-1009. doi:10.1056/NEJM199610033351401 Secondary prevention trial in 4,159 post-MI patients with average cholesterol; established that statin benefit extends to patients without overt hypercholesterolemia.
- Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357. doi:10.1056/NEJM199811053391902 9,014 patients with prior MI or unstable angina; 6.1 years follow-up; demonstrated reductions in CHD death, MI, stroke, and total mortality.
- Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630. doi:10.1016/S0140-6736(02)11600-X 5,804 men and women aged 70–82 randomized to pravastatin 40 mg or placebo for 3.2 years; established CV benefit specifically in the elderly population.
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: ALLHAT-LLT. JAMA. 2002;288(23):2998-3007. doi:10.1001/jama.288.23.2998 Open-label trial in 10,355 hypertensive patients aged ≥55 with moderate hypercholesterolemia; pravastatin 40 mg vs usual care; modest benefit attributed to small lipid difference between groups.
- Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation. 2002;105(20):2341-2346. doi:10.1161/01.CIR.0000017634.00171.24 Combined WOSCOPS, CARE, and LIPID data (>112,000 person-years); foundation for the long-term safety statements in this monograph, including the absence of severe myopathy cases at 40 mg.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625 Primary US guideline; classifies pravastatin 40–80 mg as moderate intensity and 10–20 mg as low intensity. No pravastatin dose meets high intensity (≥50% LDL-C reduction).
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455 European framework with lower LDL-C targets in very-high-risk patients; supports preferential use of high-intensity statins over pravastatin in these populations.
- Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-e81. doi:10.1161/ATV.0000000000000073 Comprehensive class-wide safety review used here for myopathy framing, observational vs RCT muscle-symptom rates, and diabetes risk discussion.
- Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2000;39(6):397-412. doi:10.2165/00003088-200039060-00002 Comprehensive PK review establishing pravastatin’s hydrophilic profile, OATP1B1 dependence, and absence of clinically significant CYP3A4 metabolism.
- Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. The effect of erythromycin on the pharmacokinetics of rosuvastatin and pravastatin. Eur J Clin Pharmacol. 2003;59(1):51-56. doi:10.1007/s00228-003-0571-9 Source for pravastatin–macrolide interaction quantification supporting the 40 mg dose cap with clarithromycin or erythromycin.
- Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557 Pharmacogenomic guidance for SLCO1B1 *5 carriers; supports the cautious dosing recommendation for poor/decreased OATP1B1 function patients.